# Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

> **NCT00488345** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 59 (actual)

## Conditions studied

- Bacterial Infections
- Intra-Abdominal Infection
- Pneumonia, Bacterial
- Skin Diseases, Bacterial
- Skin Diseases, Infectious

## Interventions

- **DRUG:** Tygacil

## Key facts

- **NCT ID:** NCT00488345
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2012-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00488345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00488345, "Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00488345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*